Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01419717
What this trial is testing

Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer

Who this might be right for
Bone Metastases in Men With Hormone-Refractory Prostate CancerBone Metastases in Subjects With Advanced Breast Cancer
Amgen 129
Large-scale testing (Phase 3)Ended earlyNCT00133224
What this trial is testing

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

Who this might be right for
Prostate Cancer
Cell Genesys 408
Early research (Phase 1)Study completedNCT00039299
What this trial is testing

Biological Therapy in Treating Patients With Prostate Cancer

Who this might be right for
Prostate Cancer
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00571675
What this trial is testing

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Who this might be right for
Hormone Refractory Prostate Cancer
Ascenta Therapeutics 220
Testing effectiveness (Phase 2)Ended earlyNCT00525408
What this trial is testing

Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer

Who this might be right for
Hormone Refractory Prostate Cancer
Cadila Pharnmaceuticals 134
Testing effectiveness (Phase 2)Study completedNCT00006002
What this trial is testing

SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
University of Chicago 36
Testing effectiveness (Phase 2)Study completedNCT00137436
What this trial is testing

Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Pfizer 93
Early research (Phase 1)Study completedNCT03854903
What this trial is testing

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Who this might be right for
Metastatic Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor Positive Breast Cancer
Georgetown University 19
Testing effectiveness (Phase 2)Study completedNCT00151073
What this trial is testing

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate

Who this might be right for
Hormone-Refractory Prostate Cancer
University of Michigan Rogel Cancer Center 28
Testing effectiveness (Phase 2)Study completedNCT00040755
What this trial is testing

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Adenocarcinoma of the ProstateBone MetastasesHormone-resistant Prostate Cancer+2 more
National Cancer Institute (NCI) 68
Large-scale testing (Phase 3)Study completedNCT00065442
What this trial is testing

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Who this might be right for
Prostate Cancer
Dendreon 512
Testing effectiveness (Phase 2)Ended earlyNCT00313482
What this trial is testing

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

Who this might be right for
Hormone Refractory Prostate Cancer
Veeda Oncology 35
Testing effectiveness (Phase 2)Ended earlyNCT01320280
What this trial is testing

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

Who this might be right for
Refractory Cancer
Universitätsklinikum Hamburg-Eppendorf 29
Early research (Phase 1)Study completedNCT05159518
What this trial is testing

PRT2527 in Participants With Advanced Solid Tumors

Who this might be right for
SarcomaCastrate Resistant Prostate CancerHormone Receptor Positive HER2 Negative Breast Cancer+2 more
Prelude Therapeutics Incorporated 30
Early research (Phase 1)Study completedNCT01971515
What this trial is testing

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

Who this might be right for
Solid Tumor
EMD Serono 101
Testing effectiveness (Phase 2)Study completedNCT00031187
What this trial is testing

Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Seagen Inc. 160
Testing effectiveness (Phase 2)Study completedNCT00278993
What this trial is testing

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Who this might be right for
Prostate Cancer
Eisai Inc. 108
Large-scale testing (Phase 3)Study completedNCT00436839
What this trial is testing

Taxotere Prostate Cancer New Indication Registration Trial in China

Who this might be right for
Prostatic Neoplasms
Sanofi 228
Testing effectiveness (Phase 2)UnknownNCT04586543
What this trial is testing

Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

Who this might be right for
Metastatic Castration-resistant Prostate CancerAdenocarcinoma of the Prostate
László Mangel 110
Testing effectiveness (Phase 2)Study completedNCT00486642
What this trial is testing

Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Who this might be right for
Hormone-Resistant Prostate CancerRecurrent Prostate Carcinoma
National Cancer Institute (NCI) 23
Next Page